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Available online 9 March 2016The human embryonic stem cell line RCe007-A (RC-3) was derived from a blastocyst voluntarily donated as un-
suitable and surplus to fertility requirements following ethics committee approved informed consent under li-
cence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal pluripotency
marker expression and differentiation to the three germ layers in vitro. It has a normal 46XX female karyotype
and HLA and blood group typing data is available.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Resource table.
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RCe007-A (RC-3) was derived from a fresh blastocyst that was
surplus to requirement or unsuitable for clinical use. The cell line was
derived by whole embryo outgrowth on mitotically inactivated
human ﬁbroblast (HDF) feeder cells using HDF conditioned medium
and expanded under feeder free conditions.
RCe007-A (RC-3) was shown to be pluripotent by expression of
Oct-4, Nanog, Sox-2, Tra-1-60 and Tra-1-81, but not SSEA-1, using
immunocytochemistry (Table 1, Fig. 1). By ﬂow cytometric analysis,
the expression of pluripotency makers Oct-4 and SSEA-4 was 86.2%
and 96.8%, respectively, whereas low expression of the differentiation
marker SSEA-1 (5.9%) was observed (Fig. 2). Differentiation to the
three germ layers, endoderm, ectoderm and mesoderm, was demon-
strated using embryoid body formation and expression of the germ
layer markers α-fetoprotein, β-tubulin and muscle actin (Fig. 3).
HLA Class I and II typing is available and blood group genotyping
gave the blood group O1O1 (Table 2).
Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding (Fig. 4)
and showed a normal 46XX female genotype. The cell line is free from
mycoplasma contamination as determined by RT-qPCR.
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Researchthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of quality control testing and results for RCe007-A (RC-3).
Classiﬁcation Test Purpose Result
Donor screening HIV 1 + 2 Donor screening for adventitious agents Negative
Hepatitis B
Hepatitis C
Phenotype Immunocytochemisty To assess levels of staining for the pluripotency
markers Oct 4 and Nanog
Expression of Oct-4, Nanog, Sox-2, Tra-1-60 and Tra-1-81
Flow cytometry Assess antigen levels & cell surface markers
commonly associated with hESC
Oct 3/4: 86.2%
SSEA-4: 96.8%
SSEA-1: 5.9%
Genotype (details provided
in Table 2)
Blood group genotyping (DNA Analysis) To establish blood group of the line O1O1
Karyology (G-banding) Conﬁrmation of normal ploidy by G-banding 46XX
HLA tissue typing To establish full HLA type I and II genotype of
the line
HLA typed Class I and Class II
Microbiology and virology Mycoplasma Mycoplasma testing by RT-qPCR Negative
Endotoxin Screening for endotoxin levels 3.18 EU/mL
Morphology Photography To capture a visual record of the line Normal
Differentiation potential Embryoid body formation To show differentiation to three germ layers Expression of muscle actin, β-tubulin and α-feto protein
594 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 593–596Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no R0136 from the UK HFEA with
informed donor consent.Cell culture
Fresh embryos were cultured EmbryoAssist (Origio (Medicult),
Denmark) until Day3 or BlastAssist (Origio) after Day 3 of development.
Embryos were cultured at 36.5–37.5 °C, 5.0± 0.5% CO2, 5.0± 0.5%O2 in
drops under parafﬁn oil (Origio) and transferred to fresh medium at
least every 2–3 days.
By Day 8 of development, or when spontaneous hatching occurred,
embryos were placed in derivation conditions consisting of mitotically
inactivated neonatal human dermal ﬁbroblasts (HDFs) (ThermoFisher
Scientiﬁc (Cascade Biologics), Paisley, UK) on tissue culture plastic
precoated with 2 μg/cm2 human laminin (Sigma Aldrich, Dorset, UK)
as per manufacturer's recommendation. If required, assisted hatching
was performed by removing the zona pellucidae mechanically using
Swemed cutting tools (Vitrolife, Göteborg, Sweden).Fig. 1. RCe007-A (RC-3) expresses pluripotency markers Oct-4, Nanog, Sox-2, Tra-1-6HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% FCS (GE
Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine
(ThermoFisher Scientiﬁc). HDF were mitotically inactivated using
gamma irradiation at 50 Gy using a Gammacell Elite 1000 machine.
For use as a feeder layer, irradiated HDFs were plated at 2–50,000
cells/cm2 in HDF conditioned medium (80% Knockout-DMEM, 20%
Knockout serum replacement (KOSR), 1 mM glutamine, 0.1 mM
β-mercaptoethanol, 1% nonessential amino acids, and 4 ng/ml human
bFGF (all ThermoFisher Scientiﬁc) over 24 h intervals over 7 days) sup-
plemented with an additional 24 ng/ml human bFGF Cells were
cultured at 36.5–37.5 °C, 5.0±0.5% CO2, 5.0± 0.5% O2 and 50%medium
exchanged 6 days a week.
The established cell line was expanded and banked using
CellStart matrix and Stempro hESC Serum Free Medium (ThermoFisher
Scientiﬁc). Passaging was performed mechanically using an EZ passage
tool (ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30
wells of a 6-well plate and cryopreserved in 0.5–1 ml KOSR based
cryopreservation solution (75% KO-DMEM, 15% Xeno-free KOSR
(ThermoFisher Scientiﬁc) and 10% DMSO (Origen Biomedical, Texas,
USA)) or Cryostor CS10 (Biolife Solution, Washington, USA).0 and Tra-1-81, but not SSEA-1. Cell nuclei are counterstained with DAPI (blue).
Fig. 2. RCe007-A (RC-3) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody or isotype control as indicated above the histograms. Percentage
staining is indicated in Table 1.
Fig. 3. In vitro differentiation of RCe007-A (RC-3) to ectoderm (β-tubulin III), mesoderm (muscle actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
counterstained with DAPI (blue).
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Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientiﬁc
(Applied Biosystems)) according to the manufacturer's instruction.Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according
to the manufacturer's instructions. Brieﬂy, an unknown sample was
compared with a standard curve of known levels of control endotoxin.
An assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980
and the CV (%) for the standard curve was ≤10%.Table 2
Blood group and HLA tissue typing results for RCe007-A (RC-3).
Blood group genotyping
RhD RhC Rhc RhE
pos pos pos neg
Jka Jkb K k
neg pos neg pos
Kp a Kp b Do a Do b
neg pos pos pos
HLA tissue typing
HLA Class I type
HLA Class II type
CommentFlow cytometry
Pluripotency was determined using the Human and Mouse
Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct-3/4 and
SSEA-4 were included as pluripotency markers, and SSEA-1 as a
differentiation marker. Fixed and permeabilised cells were analysed
using a FACS Aria ﬂow cytometer (BD).
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher
Scientiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma), muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark), Oct-4
(1:200; Santa Cruz Biotechnlogy, Texas, USA), Nanog (1:20; R&D Sys-
tems, Abingdon, UK), Sox-2, Tra-1-60, Tra-1-81, SSEA-1 (all 1:50; BD)Rhe Fy a Fy b Fy GATA
pos pos pos neg
M N S s
pos pos pos pos
ABO
O1O1
HLA-A*01; B*08, B*37; C*06, C*07
HLA-DRB1*01, DRB1*03; DRB3*01; DQB1*02, DQB1*05
DRB1*03 is expressed serologically as DR17.
Fig. 4. RCe007-A (RC-3) was analysed by Giesma staining of 20 metaphase spreads at
passage 25 and showed a normal, 46XX, female karyotype.
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mouse IgG- AlexaFluor 488, anti-goat IgG- AlexaFluor 488, anti-goat
IgG-AlexaFluor-594 and donkey polyclonal AlexaFluor-594) (all
1:200; ThermoFisher Scientiﬁc). Images were acquired using a Zeiss
S100 Axiovert ﬂuorescence microscope or Nikon eC1 confocal
microscope.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodiesEBs generated in ultra low attachment plates (Corning) for 7 days before
being transferred into EB medium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol,
1% nonessential amino acids (all ThermoFisher Scientiﬁc)), on glass
slide tissue culture chambers (Nunc, ThermoFisher Scientiﬁc) coated
with 0.5% gelatin (Sigma) at 0.1 ml/cm2 for 14 days.Genomic analysis
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular
Diagnostics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK) Live cells at 60–70% conﬂuency were shipped
overnight in warm containers, ﬁxed and analysed by standard
G-banding analysis. For research grade lines, 20 spreads were analysed.Acknowledgements
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